パーキンソン病における胃腸症候群と胃の空化に対する下頭核深部刺激の影響:体系的なレビューとメタ解析
Abdallah Abbas1, Haneen Sabet2, Youssef Hawas3
1Faculty of Medicine, Al-Azhar University, Damietta, Egypt.
Neuromodulation : journal of the International Neuromodulation Society
|September 5, 2025
まとめ
パーキンソン病 (PD) の患者の胃腸症状と胃の運動性を有意に改善します. 効果は少なくとも12ヶ月持続し 有望な治療法です
科学分野:
- 神経科学
- 胃腸内科
- 医療技術
背景:
- パーキンソン病 (PD) は,患者の生活の質に影響を与える重要な胃腸機能障害と関連しています.
- PDに関連する胃腸疾患の現在の治療法は 限られた有効性を示しています
- サブタラミック核深層脳刺激 (STN-DBS) は主に運動症状に使用されますが,胃運動などの自律的機能に影響を与える可能性があります.
研究 の 目的:
- パーキンソン病患者の胃運動と胃腸症状の改善における双方のSTN- DBSの有効性を体系的に検討し,メタ分析する.
- 非運動症状スケール (NMSS) の胃腸領域に対するSTN-DBSの影響を評価する.
- STN-DBS の後に13CO2の排泄時間 (Tmax) を用いて胃の排泄の変化を評価する.
主な方法:
- 2024年12月まで,Scopus,Web of Science,PubMed,Cochrane CENTRALのデータベースで体系的な文献検索を行いました.
- STN-DBSが胃の運動性と空化に及ぼす影響を評価する観察研究と臨床試験の含有
- 主要アウトカムに対するランダム効果モデル (NMSS-GIとTmax13CO2) を用いて行われたメタ分析.
主要な成果:
- メタアナリシスは,STN-DBS後のNMSS-GI領域スコアの有意な低下を明らかにした (MD: - 1.29, p = 0. 004).
- 6ヶ月 (MD: - 1. 46, p = 0. 001) と12ヶ月 (MD: - 1. 12, p = 0. 05) において,胃腸症状の持続的な改善が観察されました.
- 特定の刺激条件 (DBS-ON-WOM vs. DBS-OFF-WOMとDBS-ON-WOM vs. DBS前にWM) で,胃の排泄 (Tmax13CO2) の有意な改善が認められた.
結論:
- 双方のSTN- DBSは,パーキンソン病患者の胃腸症状の緩和と胃運動の強化に有意な効果を示しています.
- 胃の機能に対する肯定的な効果は,介入後12ヶ月間持続します.
- PDにおける自律機能障害に対するSTN-DBSのパラメータを最適化するために,さらなる研究が必要である.
関連する概念動画
Parkinson's Disease: Treatment
375
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
375
Gastric Emptying
1.4K
Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
1.4K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
591
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
591
Neural Regulation
39.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K
Gastrointestinal Motility Disorders
590
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
590
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702


